Search results
Results from the WOW.Com Content Network
In November 2013, the U.S. Food and Drug Administration (FDA) approved an experimental H5N1 bird flu vaccine to be held in stockpiles. [ 22 ] [ 23 ] In a clinical trial including 3,400 adults, 91% of people age 18–64 and 74% of people age 65 or older formed an immune response sufficient to provide protection.
In Russia and China a drug called arbidol is also used as a treatment. Testing of the drug has predominantly occurred in these countries and, although no clinical trials have been published demonstrating this is an effective drug, some data suggest that this could be a useful treatment for influenza. [5] [6]
Avian influenza, also known as avian flu or bird flu, is a disease caused by the influenza A virus, which primarily affects birds but can sometimes affect mammals including humans. [1] Wild aquatic birds are the primary host of the influenza A virus, which is enzootic (continually present) in many bird populations.
The Louisiana Public Health Department reported the first bird flu-related human death in the U.S. The patient, who was over 65, contracted bird flu after coming in contact with both a backyard ...
Influenza A virus subtype H5N1 (A/H5N1) is a subtype of the influenza A virus, which causes the disease avian influenza (often referred to as "bird flu"). It is enzootic (maintained in the population) in many bird populations, and also panzootic (affecting animals of many species over a wide area). [1]
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of ...
"We have antiviral medications, the same ones we use to treat regular flu, that work against this avian influenza strain," Schaffner says. The other human case of H5N1 in the U.S. in 2022 was a ...
Zanamivir is a medication used to treat and prevent influenza caused by influenza A and influenza B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza.